TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics

TRACON Pharmaceuticals, Inc. (TCON): $1.27

0.02 (-1.55%)

POWR Rating

Component Grades








Add TCON to Watchlist
Sign Up

Industry: Biotech




#27 of 348

in industry

TCON Price/Volume Stats

Current price $1.27 52-week high $14.75
Prev. close $1.29 52-week low $0.66
Day low $1.21 Volume 45,760
Day high $1.33 Avg. volume 189,119
50-day MA $1.64 Dividend yield N/A
200-day MA $3.59 Market Cap 3.40M

TCON Stock Price Chart Interactive Chart >

TRACON Pharmaceuticals, Inc. (TCON) Company Bio

Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.

TCON Latest News Stream

Event/Time News Detail
Loading, please wait...

TCON Latest Social Stream

Loading social stream, please wait...

View Full TCON Social Stream

Latest TCON News From Around the Web

Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.

Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?

Tracon Pharmaceuticals stock is rising higher on Tuesday as investors in TCON react to news of a new licensing agreement.

William White on InvestorPlace | November 21, 2023

Why Is LQR House (LQR) Stock Up 30% Today?

LQR House stock is rising higher on Tuesday after the company announced plans to repurchase up to $2 million worth of its shares.

William White on InvestorPlace | November 21, 2023

Why Is Reliance Global (RELI) Stock on the Move Today?

Reliance Global stock is on the move Tuesday after the company first announced, and then withdrew, a public offering for RELI shares.

William White on InvestorPlace | November 21, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | November 21, 2023

TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment. “We are excited

Yahoo | November 20, 2023

Read More 'TCON' Stories Here

TCON Price Returns

1-mo -14.77%
3-mo -86.09%
6-mo -64.68%
1-year -85.57%
3-year -99.05%
5-year -99.01%
YTD -63.74%
2023 -88.25%
2022 -46.21%
2021 -76.32%
2020 400.00%
2019 -62.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!